Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
On June 5, the world marks the 40th anniversary of the HIV epidemic. Biopharma researchers continue to develop safe and effective treatments with an eye to a potential cure.
Like in writing any job description, composing one for a pharmaceutical job offering must contain all the information a candidate must know.
With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news.
The three companies will aim to develop their different programs such as Stablix TPS platform, Stellanova’s focused on targeting pro-tumorigenic effects, and Amyl’s development of preclinical therapeutic candidates.
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
Nanobiotix is developing a way for its locally-injected radio enhancer NBTXR3 for solid tumors to treat metastasized cancers. Here’s what you need to know about it.
While several countries rely on Sinovac Biotech to end the pandemic, concerns regarding the shot’s efficacy continue to shroud the vaccine. Currently, it is the second most used vaccine worldwide.
It didn’t take too long before a lawsuit was filed over Bristol Myers Squibb’s failure to meet a deadline for a $9 Contingent Value Rights agreement tied to the company’s merger with Celgene.
REGEN-COV’s 1,200 mg dose is authorized to treat mild-to-moderate COVID-19 in adults and children 12 years and older who weigh 40 kilograms or more.
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
Today, the Swiss pharma titan announced the results of its Phase III VISION study, where 177Lu-PSMA-617 plus best standard of care (SOC) met both of its primary endpoints.
Organon’s focus will center on reproductive health, health conditions, and issues unique to women and diseases that disproportionately impact women.